JAK1抑制剂Upadacitinib(Rinvoq)用于治疗类风湿性关节炎的研究进展

Research Progress of JAK1 Inhibitor Upadacitinib(Rinvoq) in the Treatment of Rheumatoid Arthritis

类风湿性关节炎(RA)是一种慢性自身免疫性炎症性疾病,以关节受累、关节外表现、共病和死亡率增高为特征.Upadacitinib(Rinvoq)是口服JAK1抑制剂,由AbbVie开发用于治疗中度至重度活动性RA和对甲氨蝶呤反应不足或不耐受.本文主要介绍了Upadacitinib的合成、有效性、药代动力学、毒副作用等几个方面研究成果.

Rheumatoid arthritis(RA)is a chronic autoimmune inflammatory disease characterized by joint involvement, extra-articular manifestations, comorbidities and increased mortality.Upadacitinib(Rinvoq)is an oral JAK1 inhibitor developed by AbbVie for the treatment of rheumatoid arthritis and inadequate or intolerance to methotrexate.This article mainly introduces Upadacitinib through its synthesis, effectiveness, pharmacokinetics and toxic and side effects.